Aclaris Therapeutics Inc. (ACRS) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Comparison side by side

Both Aclaris Therapeutics Inc. (NASDAQ:ACRS) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclaris Therapeutics Inc. 6 5.86 N/A -3.97 0.00
Arrowhead Pharmaceuticals Inc. 20 29.18 N/A 0.07 262.60

We can see in table 1 the earnings per share, gross revenue and valuation of Aclaris Therapeutics Inc. and Arrowhead Pharmaceuticals Inc.


Table 2 demonstrates the return on assets, return on equity and net margins of Aclaris Therapeutics Inc. and Arrowhead Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Aclaris Therapeutics Inc. 0.00% -78% -61.8%
Arrowhead Pharmaceuticals Inc. 0.00% 6.7% 4.3%

Risk & Volatility

Aclaris Therapeutics Inc.’s 1.24 beta indicates that its volatility is 24.00% more volatile than that of S&P 500. Arrowhead Pharmaceuticals Inc.’s 106.00% more volatile than S&P 500 volatility due to the stock’s 2.06 beta.


The Current Ratio of Aclaris Therapeutics Inc. is 4.3 while its Quick Ratio stands at 4.3. The Current Ratio of rival Arrowhead Pharmaceuticals Inc. is 2.3 and its Quick Ratio is has 2.3. Aclaris Therapeutics Inc. is better equipped to clear short and long-term obligations than Arrowhead Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 97% of Aclaris Therapeutics Inc. shares are owned by institutional investors while 63.9% of Arrowhead Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 3.9% of Aclaris Therapeutics Inc. shares. Comparatively, insiders own roughly 4.2% of Arrowhead Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aclaris Therapeutics Inc. -11.72% 5.26% -17.02% -45.39% -70.16% -21.52%
Arrowhead Pharmaceuticals Inc. 4.58% 2.79% 10.94% 32.3% 103.5% 54.35%

For the past year Aclaris Therapeutics Inc. has -21.52% weaker performance while Arrowhead Pharmaceuticals Inc. has 54.35% stronger performance.


Arrowhead Pharmaceuticals Inc. beats Aclaris Therapeutics Inc. on 7 of the 8 factors.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.